Travere Therapeutics, Inc. (TVTX)
$
26.79
-0.96 (-3.58%)
Key metrics
Financial statements
Free cash flow per share
0.2879
Market cap
2.6 Billion
Price to sales ratio
5.2161
Debt to equity
2.9598
Current ratio
2.7364
Income quality
-0.7518
Average inventory
5.7 Million
ROE
-0.7916
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The weighted average number of shares outstanding is 89,211,813.00 highlighting the company's shareholder base. The net total of other income and expenses is $13,551,000.00 reflecting non-core financial activities. The income before tax ratio is -0.10 reflecting the pre-tax margin. Meanwhile, the EBITDA ratio is 0.05 highlighting the company's operational efficiency. Additionally, the weighted average number of diluted shares outstanding is 89,211,813.00 reflecting potential dilution effects as it navigates its market position. Travere Therapeutics, Inc. operates within the biopharmaceutical landscape, focusing on the identification, development, and commercialization of therapies for rare diseases. Its marketed products include Chenodal, a synthetic oral formulation for treating radiolucent stones in gallbladders, Cholbam, a cholic acid capsule for various bile acid synthesis disorders, and Thiola and Thiola EC for treating homozygous cystinuria. Additionally, the company's product candidates include Sparsentan and TVT-058, targeting serious nephrological conditions through clinical trials. Through its cooperative research and development agreements, Travere seeks to advance treatment options for conditions such as NGLY1 deficiency and Alagille syndrome. The stock is affordable at $24.85 suitable for budget-conscious investors. The stock has a high average trading volume of 2,029,313.00 indicating strong liquidity in the marketplace. With a market capitalization of $2,471,151,125.00 the company is classified as a small-cap player within the industry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the healthcare sector, driving innovation and growth while maintaining a commitment to improving the lives of patients with rare diseases. Through its structured approach and dedicated research, Travere Therapeutics continues to make strides in advancing therapeutic solutions, positioning itself as a vital entity in the quest for novel treatments for challenging health conditions.
Is Travere Therapeutics, Inc. (TVTX) a good investment?
Investing in Travere Therapeutics, Inc. (TVTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Travere Therapeutics, Inc. (TVTX)'s stock forecast?
Analysts predict Travere Therapeutics, Inc. stock to fluctuate between $12.91 (low) and $42.13 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Travere Therapeutics, Inc.'s market capitalization?
As of 2026-03-25, Travere Therapeutics, Inc.'s market cap is $2,471,151,125, based on 92,241,550 outstanding shares.
How does Travere Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Travere Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Travere Therapeutics, Inc. (TVTX) stock?
To buy Travere Therapeutics, Inc. (TVTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TVTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Travere Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Travere Therapeutics, Inc. stock ever split?
Travere Therapeutics, Inc.'s last stock split was 1:9 on 2012-11-02.
How did Travere Therapeutics, Inc. perform in the last earnings report?
Revenue: $490,728,000 | EPS: -$0.56 | Growth: -86.27%.
Where can I find Travere Therapeutics, Inc.'s investor relations reports?
Visit https://www.travere.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Travere Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Travere Therapeutics, Inc. stock?
All-time high: $42.13 (2025-12-24) | All-time low: $5.12 (2024-04-25).
What are the key trends affecting Travere Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. FY25 revenue grew 81% to $410.5M, driven by FILSPARI's 144% YoY growth and record patient starts, signaling robust commercial momentum. Profitability metrics improved, with 4Q25 GAAP net income positive and non-GAAP net income at $81.1M, reflecting operating leverage and cost discipline.
seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
zacks.com
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.73 per share a year ago.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We.
globenewswire.com
SAN DIEGO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.
prnewswire.com
SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.
globenewswire.com
BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their Travere Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.
fool.com
Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM).
See all news
